Carboplatin (Paraplatin®)

Two Cytoreductive Surgeries Can Improve Survival for Peritoneal Mesothelioma Patients

If peritoneal mesothelioma patients undergo a second surgery after recurrence, they can improve their survival. Data from a retrospective review from Wake Forest Baptist Medical Center shows that cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC) can be incredibly helpful for peritoneal disease sufferers. For some people, a second surgery has[…]

Read More »

Checkmate 743 Shows Immunotherapy is Better for Mesothelioma Patients Who Cannot Receive Surgery

A clinical trial called Checkmate 743, which looks at the immunotherapy drugs nivolumab (Opdivo) and ipilimumab (Yervoy), shows that the combination can create a better quality of life when compared with the chemotherapy drugs pemetrexed, cisplatin, and carboplatin. Patient reported outcomes were recently reported. People who took Opdivo and Yervoy[…]

Read More »

New Clinical Trial Testing Effectiveness of Immunotherapy and Chemotherapy Before Surgery

Mesothelioma, the cancer of the linings of different organs, but primarily the lungs, has a poor prognosis and survival rate for those who are diagnosed. Since there is no cure, treatments helping to extend people’s lives need to be tested. Clinical trials help doctors find new ways to treat mesothelioma[…]

Read More »

Survival Improves in Mesothelioma Patients who Received an Electricity-Based Treatment

The success of a recent Phase II clinical trial in malignant pleural mesothelioma has scientists and researchers excited about the possibility of adding a new treatment that will not only improve survival, but also improve quality of life of the cancer patient. Tumor Treating Fields, which is a therapy that[…]

Read More »

Adding an inhibitor to mesothelioma treatment proves effective

A recent mesothelioma study found the addition of bevacizumab to the chemotherapy treatment of pemetrexed plus cisplatin may increase the survival rate in patients. From 2008 to 2014, patients were given the standard treatment in 21-day increments for six cycles, with some receiving bevacizumab. The addition of bevacizumab increased survival[…]

Read More »